I think this is missing the point. I don't think anyone is arguing that pharma spends a lot on marketing and that this cost is passed on to consumers. Rather, the point being made is that the US system disproportionately funds pharma R&D. Meaning, if the idea is to have parity with other countries, at least one of several options needs to happen: 1) other countries start funding more R&D, 2) other countries drug prices increase, 3) we accept that less R&D occurs, or 4) we find alternative sources for funding R&D.

Glib answers like "just do what other countries do" don't address any of that.